Lung Neoplasm
93
14
16
45
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.5%
6 terminated out of 93 trials
88.2%
+1.7% vs benchmark
8%
7 trials in Phase 3/4
20%
9 of 45 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 45 completed trials
Clinical Trials (93)
Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Mid-point Transverse Process to Pleura Block Versus Thoracic Paravertebral Block in Posterolateral Thoracotomy
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
Facilitating Communication Study
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Feasibility of Mobile-CT-Assisted Bronchoscopy for the Diagnosis of Lung Lesion